These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 30606789)

  • 1. Six months
    Couturaud F; Pernod G; Presles E; Duhamel E; Jego P; Provost K; Pan-Petesch B; Sollier CBD; Tromeur C; Hoffmann C; Bressollette L; Lorillon P; Girard P; Le Moigne E; Le Hir A; Guégan M; Laporte S; Mismetti P; Lacut K; Bosson JL; Bertoletti L; Sanchez O; Meyer G; Leroyer C; Mottier D;
    Haematologica; 2019 Jul; 104(7):1493-1501. PubMed ID: 30606789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial.
    Couturaud F; Sanchez O; Pernod G; Mismetti P; Jego P; Duhamel E; Provost K; dit Sollier CB; Presles E; Castellant P; Parent F; Salaun PY; Bressollette L; Nonent M; Lorillon P; Girard P; Lacut K; Guégan M; Bosson JL; Laporte S; Leroyer C; Décousus H; Meyer G; Mottier D;
    JAMA; 2015 Jul; 314(1):31-40. PubMed ID: 26151264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial.
    Prandoni P; Prins MH; Lensing AW; Ghirarduzzi A; Ageno W; Imberti D; Scannapieco G; Ambrosio GB; Pesavento R; Cuppini S; Quintavalla R; Agnelli G;
    Ann Intern Med; 2009 May; 150(9):577-85. PubMed ID: 19414836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial.
    Campbell IA; Bentley DP; Prescott RJ; Routledge PA; Shetty HG; Williamson IJ
    BMJ; 2007 Mar; 334(7595):674. PubMed ID: 17289685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study.
    Siragusa S; Malato A; Saccullo G; Iorio A; Di Ianni M; Caracciolo C; Coco LL; Raso S; Santoro M; Guarneri FP; Tuttolomondo A; Pinto A; Pepe I; Casuccio A; Abbadessa V; Licata G; Battista Rini G; Mariani G; Di Fede G
    Am J Hematol; 2011 Nov; 86(11):914-7. PubMed ID: 21953853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study.
    Piazza G; Mani V; Goldhaber SZ; Grosso MA; Mercuri M; Lanz HJ; Schussler S; Hsu C; Chinigo A; Ritchie B; Nadar V; Cannon K; Pullman J; Concha M; Schul M; Fayad ZA;
    Vasc Med; 2016 Aug; 21(4):361-8. PubMed ID: 27165711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
    Andreozzi GM; Bignamini AA; Davì G; Palareti G; Matuška J; Holý M; Pawlaczyk-Gabriel K; Džupina A; Sokurenko GY; Didenko YP; Andrei LD; Lessiani G; Visonà A;
    Circulation; 2015 Nov; 132(20):1891-7. PubMed ID: 26408273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
    Agnelli G; Prandoni P; Santamaria MG; Bagatella P; Iorio A; Bazzan M; Moia M; Guazzaloca G; Bertoldi A; Tomasi C; Scannapieco G; Ageno W;
    N Engl J Med; 2001 Jul; 345(3):165-9. PubMed ID: 11463010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial Protocol: a randomised controlled trial of extended anticoagulation treatment versus routine anticoagulation treatment for the prevention of recurrent VTE and post thrombotic syndrome in patients being treated for a first episode of unprovoked VTE (The ExACT Study).
    Tullett J; Murray E; Nichols L; Holder R; Lester W; Rose P; Hobbs FD; Fitzmaurice D
    BMC Cardiovasc Disord; 2013 Mar; 13():16. PubMed ID: 23497371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prolongation of anti vitamin K treatment for 18 months versus placebo after 6 months treatment of a first episode of ideopathic pulmonary embolism: a mutlicentre, randomised double blind trail. The PADIS-EP Trial].
    Couturaud F; Pernod G; Pison C; Mismetti P; Sanchez O; Meyer G; Parent F; Girard P; Simonneau G; Drouet L; Gueret P; Jego P; Delaval P; Duhamel E; Gruel Y; Delahousse B; Regina S; Pottier P; Connaud J; Lecomte F; Provost K; Vilmans N; Gosset X; Bura-Rivière A; Meach G; Lacut K; Bosson JL; Guillot K; Mottier D; Leroyer C
    Rev Mal Respir; 2008 Sep; 25(7):885-93. PubMed ID: 18946418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-dimer testing to determine the duration of anticoagulation therapy.
    Palareti G; Cosmi B; Legnani C; Tosetto A; Brusi C; Iorio A; Pengo V; Ghirarduzzi A; Pattacini C; Testa S; Lensing AW; Tripodi A;
    N Engl J Med; 2006 Oct; 355(17):1780-9. PubMed ID: 17065639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inconsistencies in the planning of the duration of anticoagulation among outpatients with acute deep-vein thrombosis. Results from the OTIS-DVT Registry.
    Spirk D; Husmann M; Willenberg T; Banyai M; Frank U; Baldi T; Amann-Vesti B; Baumgartner I; Kucher N
    Thromb Haemost; 2011 Feb; 105(2):239-44. PubMed ID: 20886197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial.
    Ageno W; Bertù L; Bucherini E; Camporese G; Dentali F; Iotti M; Lessiani G; Parisi R; Prandoni P; Sartori M; Visonà A; Bigagli E; Palareti G;
    BMJ; 2022 Nov; 379():e072623. PubMed ID: 36520715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.
    Prandoni P; Noventa F; Ghirarduzzi A; Pengo V; Bernardi E; Pesavento R; Iotti M; Tormene D; Simioni P; Pagnan A
    Haematologica; 2007 Feb; 92(2):199-205. PubMed ID: 17296569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
    Kearon C; Gent M; Hirsh J; Weitz J; Kovacs MJ; Anderson DR; Turpie AG; Green D; Ginsberg JS; Wells P; MacKinnon B; Julian JA
    N Engl J Med; 1999 Mar; 340(12):901-7. PubMed ID: 10089183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
    Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
    Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation period in idiopathic venous thromboembolism. How long is enough?
    Farraj RS
    Saudi Med J; 2004 Jul; 25(7):848-51. PubMed ID: 15235686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.